Diagnoplex Receives $1.4M from Investors to Support Colon Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Diagnoplex and Debiopharm Diagnostics, part of the Debiopharm Group, today announced that Diagnoplex has secured CHF1.3 million ($1.4 million) in financing.

Debiopharm led the round, while Neomed and Capital Romandie also participated in the financing.

Diagnoplex will use the funds to support its efforts to obtain CE marking for Colox, a non-invasive, blood-based test for the early detection of colorectal cancer. The Lausanne, Switzerland-based firm also hopes to prepare a comparative clinical trial for Colox.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.